Barclays Opens U.S. Large-Cap Biopharma Coverage, Names Four Preferred Stocks
Barclays has begun coverage of U.S. large-cap biopharmaceuticals with a Neutral stance, identifying Eli Lilly, Merck, Bristol-Myers Squibb and AbbVie as its top picks. The bank cites improved policy clarity after most-favored-nation agreements, demographic and healthcare spending trends, and AI-driven productivity gains as reasons the sector could …